Ortega PAQ, Silva MMA, Gaona VLS

Language: Spanish
References: 29
Page: 93-99
PDF size: 164.47 Kb.

ABSTRACT

Introduction: The politraumatized patients develop a systemic inflammatory response and quimiotaxis cascade like the infectious diseases; from this kind of patients, those with severe traumatic brain injury, need to hold medium arterial pressure ≥ 90 mmHg, that triggers high doses of vasopressor.
Objective: Evaluate hemodynamic repercussion, of infusion Vasopressin/Norepinephrine (experimental group) vs Norepinephrine (control group) in politraumatized patients with severe traumatic brain injury whom present hemodynamic instability.
Material and methods: Controlled, non randomized and open trial, with parallel groups.
Results: We got a standardized sample of 20 patients; both groups had the same median of mean arterial pressure (MAP) [experimental group 90 versus control group 93 mmHg, p = 0.516]. There were better hemodynamic effect in experimental group, in systolic arterial pressure (SAP) [first hour, p = .041], heart rate (HR) [first hour p = .029], and lactate [hour 5, p = .015]. The fluid balance’s median in control group was +1,516 mL versus +553 mL in experimental group [p = 0.579].
Conclusion: There was no significant difference in MAP of both groups, in reanimation period either neurological protection therapy. There was statistically significant improvement in SAP and HR, in experimental group.

REFERENCES

1. Errington ML, Rocha M, Silva E Jr. The secretion and clearance of vasopressin during the development of irreversible haemorrhagic shock. J Physiol (Lond). 1971;217:43-45.

2. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D’Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95(5):1122-1125.

3. Wenzel V, Lindner KH, Prengel AW, Maier C, Voelckel W, Lurie KG, et al. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcounter shock pulseless electrical activity in pigs. Critical Care Medicine. 1999;27(3):486-492.

4. Robertson GL. The regulation of vasopressin functions in health and disease. Recent Prog Horm Res. 1976;33:333-385.

5. Leng G, Brown CH, Russell JA. Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol. 1999;57(6):625-655.

6. Sklar AH, Schrier RW. Central nervous system mediators of vasopressin release. Physiol Rev. 1983;63(4):1243-1280.

7. Bourque CW, Oliet SH, Richard D. Osmoreceptors, osmoreception and osmoregulation. Front Neuroendocrinol. 1994;15(3):231-274.

8. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol. 1979;236(4):F321-F332.

9. Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int. 1976;10(1):25-37.

10. Thrasher TN. Baroreceptor regulation of vasopressin and renin secretion: low-pressure versus high-pressure receptors. Front Neuroendocrinol. 1994;15(2):157-196.

11. Reid IA. Role of nitric oxide in the regulation of renin and vasopressin secretion. Front Neuroendocrinol. 1994;15(4):351-383.

12. Bichet DG. Vasopressin receptors in health and disease. Kidney Int. 1996;49(6):1706-1711.

13. Riphagen CL, Pttman QJ. Arginine vasopressin as a central neurotransmitter. Fed Proc. 1986;45(9):2318-2322.

14. Ramírez MS, Gutiérrez VI, Domínguez MA, Barba FC. Respuesta metabólica al trauma. Medicrit. 2008;5(4):130-133.

15. Rodríguez ND, Rodríguez AM, Alfonso AL, Castellanos PE, Reyes MM, Quintana RM. Metabolic response in trauma. Revista Cubana de Medicina Militar. 2012;41(1):96-104.

16. Cuacuas CV, Escobar MM, Torres MJ, Hernández AE. Trauma de alta energía y su respuesta inflamatoria sistémica. Ortho-tips. 2008;4(1):39-50.

17. Alted L, Bermejo A, Chico F. Actualizaciones en el manejo del traumatismo craneoencefálico grave. Med Intensiva. 2009;33(1):16-30.

18. Carrillo ER, Leal GP. Actualidades de fármacos vasopresores e inotrópicos en anestesia. Rev Mex Anest. 2009;32(1):S74-S76.

19. Chandler D, Waterhouse B, Wen-Jun G. New perspectives on catecholaminergic regulation of executive circuits. Front Neural Circuits. 2014;21(8):53-63.

20. Haddad SH, Arabi YM. Critical care management of severe traumatic brain injury in adults. Scand J Trauma Resusc Emerg Med. 2012;20:12.

21. Voelckel WG, Raedler C, Wenzel V, Lindner KH, Krismer AC, Schmittinger CA, et al. Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Crit Care Med. 2003;31(4):1160-1165.

22. Sanui M, King DR, Feinstein AJ, Varon Aj. Effects of argininavasopresina during resuscitation from hemorrhagic hypotension after traumatic brain injury. Crit Care Med. 2006;34:433-438.

23. Lienhart HG, Wenzel V, Braun J, Dörges V, Dünser M, Gries A, et al. Vasopressin for therapy of persistent traumatic hemorrhagicshock: the VITRIS study. Anaesthesist. 2007;56(2):145-148.

24. Lienhart HG, Lindner KH, Wenzel V. Developing alternative strategies for the treatment of traumatic. Curr Opin Crit Care. 2008;14(3):247-253.

25. Chico-Fernández M, Llompart-Pou JA, Guerrero-López F, Sánchez-Casado M, García-Sáez I, Mayor-García MD, et al. Epidemiology of severe trauma in Spain. Registry of trauma in the ICU (RETRAUCI). Med Intensiva. 2016;40(6):327-347.

26. Russell JA, Walley KR, Singer J, et al. Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock (VASST). N Engl J Med. 2008;358:877-87.

27. Luckner G. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med. 2005;33(11):2659-2666.

28. Birkhahn RH, Gaeta TJ, Terry D, Bove JJ, Tloczkowski J. Shock index in diagnosing early acute hypovolemia. Am J Emerg Med. 2005;23(3):323-326.

29. Acheampong A, Vincent JL. A positive fluid balance is an independent prognostic factor in patients with sepsis. Crit Care. 2015;19:251.